 SELLAS Life Sciences Group, Inc. is a late-stage biopharmaceutical company developing novel cancer immunotherapies. Sellas is currently progressing two therapeutics GalinPepimut-S Phase 3, Fast Track, ODD and Nelipepimut-S Phase 2 across 4 indications with GPS aiming for a 2023 approval in CR2 AML. 